English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Malignant gliomas (MG) are one of the deadliest cancers with very limited therapeutic options. Chimeric antigen receptor (CAR)-T cell therapy has emerged as a powerful strategy for B-cell malignancies and may offer new opportunities to improve outcomes for patients with MGs. Our team is clinically evaluating IL13Rα2-targeted CAR-T cells for the treatment of recurrent IL13Rα2-positive MGs [NCT02208362]. While this trial is ongoing, we have previously reported that one patient with recurrent multifocal glioblastoma achieved a complete response post-IL13Rα2-CAR-T therapy despite the non-uniform expression of IL13Rα2 on the tumor. The therapeutic response against IL13Rα2-negative cells suggests CAR-T cells may stimulate endogenous immune responses. To study the interplay between CAR-T cells and host immune subsets, we have established a syngeneic immunocompetent glioma model, which recapitulates the tumor microenvironment (TME) of patients. Murine IL13Rα2-CAR-T cells mediate potent antitumor activity against IL13Rα2-engineered KR158, a highly invasive murine glioma model. Interestingly, mice “cured” from CAR-T therapy, after rechallenge, can successfully reject the tumors. Furthermore, we demonstrate comparable response rate in mice bearing gliomas with mixed antigen expression (50%IL13Rα2+/50%IL13Rα2-) vs 100% IL13Rα2+. Characterization of the TME post-CAR-T therapy indicates activation of endogenous cytotoxic CD8 T and myeloid cells, and decrease in the frequency of T regulatory cells. Further analyses reveal that tumor-associated macrophages (TAMs) may be reprogrammed during CAR-T therapy to exhibit tumoricidal activity and may promote the activation of endogenous T cells (CD4/CD8 T cells) resulting in enhanced antitumor activity. Current studies are focusing on the characterization of host immune cells to identify the mechanisms involved in induction of host immune responses mediated by CAR-T cell therapy. Our data thus strongly suggest that CAR-T therapy has the potential to reshape the glioma microenvironment creating a context permissible to elicit effective endogenous antitumor immunity.

IMMU-12. IL13Ra2-CAR T CELLS STIMULATE ENDOGENOUS IMMUNE RESPONSES AGAINST MURINE GLIOBLASTOMAS